Mydecine Innovations Group (DB:0NF0) - Stock Price, News & Analysis

0NF0 Stock Overview

A biotechnology company, engages in the research, development, and commercialization of psilocybin products to treat mental health conditions. More details

0NF0 fundamental analysis
Snowflake Score
Valuation	0/6
Future Growth	0/6
Past Performance	0/6
Financial Health	0/6
Dividends	0/6

Rewards

Earnings have grown 8.7% per year over the past 5 years

Risk Analysis

Makes less than USD$1m in revenue (CA$0)

Does not have a meaningful market cap (€333K)

Has less than 1 year of cash runway

Negative shareholders equity

+ 2 more risks

Mydecine Innovations Group Inc. Competitors

Biofrontera

XTRA:B8FK

€15.4m

SynBiotic

DUSE:SBX

€27.9m

MPH Health Care

DB:93M1

€101.9m

Redx Pharma

DB:0RX

€65.0m

Price History & Performance

Summary of all time highs, changes and price drops for Mydecine Innovations Group
Historical stock prices
Current Share Price	US$0.0035
52 Week High	US$0.076
52 Week Low	US$0.0005
Beta	2.77
11 Month Change	16.67%
3 Month Change	-76.67%
1 Year Change	-95.33%
33 Year Change	-99.94%
5 Year Change	n/a
Change since IPO	-100.00%

Recent updates

Shareholder Returns

	0NF0	DE Pharmaceuticals	DE Market
7D	16.7%	1.2%	1.3%
1Y	-95.3%	-19.7%	7.9%

Return vs Industry: 0NF0 underperformed the German Pharmaceuticals industry which returned -19% over the past year.

Return vs Market: 0NF0 underperformed the German Market which returned 7.2% over the past year.

Price Volatility

Is 0NF0's price volatile compared to industry and market?
0NF0 volatility
0NF0 Average Weekly Movement	120.6%
Pharmaceuticals Industry Average Movement	6.9%
Market Average Movement	4.8%
10% most volatile stocks in DE Market	10.8%
10% least volatile stocks in DE Market	2.4%

Stable Share Price: 0NF0's share price has been volatile over the past 3 months compared to the German market.

Volatility Over Time: 0NF0's weekly volatility has decreased from 633% to 121% over the past year, but is still higher than 75% of German stocks.

About the Company

Founded	Employees	CEO	Website
2013	3	Josh Bartch	www.mydecine.com

Mydecine Innovations Group Inc., a biotechnology company, engages in the research, development, and commercialization of psilocybin products to treat mental health conditions. The company primarily focuses on treating nicotine addiction and post-traumatic stress disorder. Its lead product drug candidates include MYCO-005.

Mydecine Innovations Group Inc. Fundamentals Summary

How do Mydecine Innovations Group's earnings and revenue compare to its market cap?
0NF0 fundamental statistics
Market cap	€315.97k
Earnings (TTM)	-€8.43m
Revenue (TTM)	n/a

0.0x

P/S Ratio

0.0x

P/E Ratio

Is 0NF0 overvalued?

See Fair Value and valuation analysis

Earnings & Revenue

Key profitability statistics from the latest earnings report (TTM)
0NF0 income statement (TTM)
Revenue	CA$0
Cost of Revenue	CA$0
Gross Profit	CA$0
Other Expenses	CA$12.46m
Earnings	-CA$12.46m

Last Reported Earnings

Sep 30, 2024

Next Earnings Date

n/a

Earnings per share (EPS)	-0.20
Gross Margin	0.00%
Net Profit Margin	0.00%
Debt/Equity Ratio	-37.4%

How did 0NF0 perform over the long term?

See historical performance and comparison

0NF0 Stock Overview

Rewards

Risk Analysis

Mydecine Innovations Group Inc. Competitors

XTRA:B8FK

€15.4m

DUSE:SBX

€27.9m

DB:93M1

€101.9m

DB:0RX

€65.0m

Price History & Performance

Recent News & Updates

New major risk - Financial position

New minor risk - Financial data availability

Mydecine Innovations Group Inc., Annual General Meeting, Jul 05, 2024

Mydecine Innovations Group Inc. announced that it expects to receive CAD 1 million in funding

Mydecine Innovations Group Inc Announces Resignation of Neil Stevenson-Moore as Director

Mydecine Innovations Group Inc. has completed a Follow-on Equity Offering in the amount of CAD 1.104 million.

Recent updates

New major risk - Financial position

New minor risk - Financial data availability

Mydecine Innovations Group Inc., Annual General Meeting, Jul 05, 2024

Mydecine Innovations Group Inc. announced that it expects to receive CAD 1 million in funding

Mydecine Innovations Group Inc Announces Resignation of Neil Stevenson-Moore as Director

Mydecine Innovations Group Inc. has completed a Follow-on Equity Offering in the amount of CAD 1.104 million.

Mydecine Innovations Group Inc. has completed a Follow-on Equity Offering in the amount of CAD 3.75 million.

Mydecine Innovations Group Inc. has completed a Follow-on Equity Offering in the amount of CAD 3.75 million.

Mydecine Innovations Group Inc. Appoints John Ross as Corporate Secretary

Mydecine Innovations Group Inc. has completed a Follow-on Equity Offering in the amount of CAD 5 million.

Mydecine Innovations Group Inc., Annual General Meeting, Apr 20, 2023

Mydecine Innovations Group Inc. has completed a Follow-on Equity Offering in the amount of CAD 5 million.

Pangenomic Health Inc. (CNSX:NARA) completed the acquisition of Mindleap Health Inc. from Mydecine Innovations Group Inc. (OTCPK:MYCO.F).

Mydecine Innovations Group Inc. has completed a Follow-on Equity Offering in the amount of CAD 4.5 million.

Mydecine Innovations Group Inc. has completed a Follow-on Equity Offering in the amount of CAD 0.5 million.

Mydecine Innovations Group Inc. has completed a Follow-on Equity Offering in the amount of CAD 0.5 million.

Less than half of directors are independent

Mydecine Innovations Group Inc. Announces Appointment of John Ross as Its Chief Financial Officer

Mydecine Innovations Group Inc. has completed a Follow-on Equity Offering.

Pangenomic Health Inc. (CNSX:NARA) signed an arm's length non binding Letter of Intent to acquire Mindleap Health Inc. from Mydecine Innovations Group Inc. (OTCPK:MYCO.F) for CAD 4 million.

Mydecine Innovations Group Inc. Files Full Patent Application Covering MYCO-006 Family of Novel Short-Acting Mdma Analogs

Mydecine Innovations Group Announces CFO Changes

Mydecine Innovations Group Inc. Announces Resignation of Directors

Mydecine Files Full Patent Application Covering Myco-006 Family of Novel Short-Acting Mdma Analogs

Mydecine Innovations Group Announces U.S. FDA Clears MYCO-001 for Multi-Site Government Funded Trial in Smoking Cessation

Mydecine Innovations Group Inc. Announces Board Changes

Mydecine Innovations Group Inc. has completed a Composite Units Offering in the amount of CAD 4 million.

Mydecine Innovations Group Inc. has completed a Composite Units Offering.

First quarter 2022 earnings released: CA$1.20 loss per share (vs CA$1.25 loss in 1Q 2021)

High number of new and inexperienced directors

Mydecine Innovations Group Inc., Annual General Meeting, May 26, 2022

Full year 2021 earnings released

Mydecine Innovations Group Inc. Reports Positive Pre-IND Meeting with FDA for MYCO-001 Smoking Cessation Study

Mydecine Announces MYCO-005 Family of Improved Safety Microdose Novel Molecules

Mydecine Innovations Group Inc. to Launch Special Access Support and Supply Program in Canada Expanding Access to Psychedelic- Assisted Psychotherapy for Patients

Mydecine Innovations Group Inc. Submits Pre-Investigational New Drug Briefing Package to the FDA for MYCO-001 Seamless Phase 2/3 Smoking Cessation Clinical Trial

Mydecine Innovations Group Inc. Achieves Innovative Supercomputing Artificial Intelligence Modeling in Psychedelic Drug Development Enabling Quick Screening of Billions of Compounds

Mydecine Innovations Group Inc. announced that it expects to receive CAD 5.5 million in funding

Mydecine Files Full Patent Application Covering Multiple Families of Psilocin Analogs

Third quarter 2021 earnings released: CA$0.019 loss per share (vs CA$0.11 loss in 3Q 2020)

Mydecine Innovations Group Files MYCO-003 Final Patent Application and Reports Positive Preclinical Data

Second quarter 2021 earnings released: CA$0.016 loss per share (vs CA$0.046 loss in 2Q 2020)

Mydecine Provides Business Update

Mydecine Innovations Group Expands Portfolio of Novel Molecules Filing New Patent for MDMA-Like Compounds

Mydecine Selects Substance Use Disorder and Smoking Cessation for Novel Psychedelic Molecule MYCO-004

Mydecine Unveils Artificial Intelligence Drug Discovery Program

Mydecine Innovations Group Discovers over 40 Groundbreaking Potential Pharmacologically Active Novel Compounds in Mushrooms

Health Canada Approves Expansion of Mydecine's Cultivation Capabilities for Psilocybin Producing Mushrooms

Health Canada Approves Expansion of Mydecine’s Cultivation Capabilities for Psilocybin Producing Mushrooms

First quarter 2021 earnings released: CA$0.025 loss per share (vs CA$0.006 loss in 1Q 2020)

Mydecine Innovations Group Announces Management Changes

Mydecine Fully Completes the First-Ever International Export of Psilocybin Mushrooms and Solidifies Its Clinical and Commercial Supply Chain

Mydecine Announces Exclusive Partnership and Increased Capabilities with Applied Pharmaceutical Innovation (API) at the University of Alberta

Chief Compliance Officer ? recently sold €783k worth of stock

Mydecine Innovations Group Inc. has completed a Composite Units Offering in the amount of CAD 15 million.

Mydecine Innovations Group Announces Management Changes

Mydecine Innovations Group Appoints Gordon Neal to Board of Directors

Mydecine Innovations Group Announces the Filing of Seven Provisional Patent Applications with the United States Patent and Trademark Office

Mydecine Innovations Group Engages the ProPharma Group to Proceed with FDA Filings and Approval for Novel Research and Multiple Phase Clinical Trials